ERBB2 and breast carcinoma: T-DM1 + Tucatinib: The combination of T-DM1 with tucatinib has shown promising results in the treatment of advanced or metastatic HER2-positive breast cancer, as demonstrated in the HER2CLIMB-02 trial (NCT03975647):